Entrada Therapeutics, Inc. (TRDA): Price and Financial Metrics
TRDA Price/Volume Stats
| Current price | $12.72 | 52-week high | $18.44 |
| Prev. close | $12.89 | 52-week low | $10.62 |
| Day low | $12.52 | Volume | 49,596 |
| Day high | $13.01 | Avg. volume | 78,322 |
| 50-day MA | $13.42 | Dividend yield | N/A |
| 200-day MA | $14.82 | Market Cap | 427.40M |
TRDA Stock Price Chart Interactive Chart >
Entrada Therapeutics, Inc. (TRDA) Company Bio
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest TRDA News From Around the Web
Below are the latest news stories about ENTRADA THERAPEUTICS INC that investors may wish to consider to help them evaluate TRDA as an investment opportunity.
Iovance (IOVA) Falls After Clinical Update on Lung Cancer DrugIovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines. |
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca OnbodyThe FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news. |
Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 SharesKory Wentworth, the CFO of Entrada Therapeutics Inc (NASDAQ:TRDA), executed a sale of 12,500 shares in the company on December 26, 2023, according to a recent SEC Filing. |
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer CandidateThe FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises. |
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive CandidiasisCidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%. |
TRDA Price Returns
| 1-mo | -0.47% |
| 3-mo | -17.99% |
| 6-mo | -13.17% |
| 1-year | -29.37% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -15.71% |
| 2023 | 11.61% |
| 2022 | -21.03% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...